October 8, 2015 News by Patricia Silva, PhD Acorda To Present New Data on MS Therapies AMPYRA and Experimental rHIgM22 at #ECTRIMS2015 Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1 clinical trial evaluating rHIgM22, and five-year post-marketing safety data on AMPYRA® (dalfampridine) Extended Release Tablets (10 mg) at this year’s 31st Congress of the European Committee for Treatment and Research in…
September 12, 2014 News by Maureen Newman Real-World Analysis of AMPYRA Multiple Sclerosis Drug Presented by Acorda and HealthCore Acorda Therapeutics will present results of a study analyzing AMPYRA (dalfampridine) Extended Release Tablets in multiple sclerosis patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, held through September 10-13. Unlike many other studies of therapeutic agents, this study looked at prescribing patterns, patient compliance, and budget impact…
June 30, 2014 News by Patricia Silva, PhD Actavis Plans Generic Version of Acorda’s Multiple Sclerosis Drug Ampyra Acorda Therapeutics recently announced receiving a notice letter from pharmaceutical company Actavis Plc indicating their plans to commercialize a generic version of Ampyra, Acorda’s multiple sclerosis treatment drug. Acorda claims that Actavis submitted a marketing approval application with the U.S. Food and Drug Administration (FDA) asking permission to develop and commercialize a new drug,…
